41 related articles for article (PubMed ID: 34388030)
1. High Expression of
Wang X; Bi Y; Liu X; Liu L; Hao M; Tian M; Shang J
Cancer Biother Radiopharm; 2022 May; 37(4):313-323. PubMed ID: 34388030
[No Abstract] [Full Text] [Related]
2. Functional analysis of ESM1 by shRNA-mediated knockdown of its expression in papillary thyroid cancer cells.
Xie L; He L; Zhang W; Wang H
PLoS One; 2024; 19(4):e0298631. PubMed ID: 38626010
[TBL] [Abstract][Full Text] [Related]
3. Translocated HMGB3 is involved in papillary thyroid cancer progression by activating cytoplasmic TLR3 and transmembrane TREM1.
Zhao Y; Lv HJ; Deng XY; Chen P; Garstka MA; Shi BY; Fu J
Cell Cycle; 2023; 22(23-24):2584-2601. PubMed ID: 38197217
[TBL] [Abstract][Full Text] [Related]
4. Effect of silencing CITED1 gene to regulate PI3K/AKT pathway on the biological function of PTC cells and its mechanism.
Chen W; Yu J; Xie R; Zhang S; Zhou T; Xiong C; Huang D; Zhong M
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):113-117. PubMed ID: 37807325
[TBL] [Abstract][Full Text] [Related]
5. SRPX2 promotes cancer cell proliferation and migration of papillary thyroid cancer.
Guo H; Liu R; Wu J; Li S; Yao W; Xu J; Zheng C; Lu Y; Zhang H
Clin Exp Med; 2023 Dec; 23(8):4825-4834. PubMed ID: 37306872
[TBL] [Abstract][Full Text] [Related]
6. YTHDC2 Retards Cell Proliferation and Triggers Apoptosis in Papillary Thyroid Cancer by Regulating CYLD-Mediated Inactivation of Akt Signaling.
Zhou G; Wang S
Appl Biochem Biotechnol; 2024 Jan; 196(1):588-603. PubMed ID: 37162682
[TBL] [Abstract][Full Text] [Related]
7. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid Cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract][Full Text] [Related]
8. A tumor-suppressing role of TSPYL2 in thyroid cancer: Through interacting with SIRT1 and repressing SIRT1/AKT pathway.
Zhang X; Wu X; Yao W; Wang YH
Exp Cell Res; 2023 Nov; 432(1):113777. PubMed ID: 37696385
[TBL] [Abstract][Full Text] [Related]
9. SKP2 Contributes to AKT Activation by Ubiquitination Degradation of PHLPP1, Impedes Autophagy, and Facilitates the Survival of Thyroid Carcinoma.
Shao Y; Ren W; Dai H; Yang F; Li X; Zhang S; Liu J; Yao X; Zhao Q; Sun X; Zheng Z; Xu C
Mol Cells; 2023 Jun; 46(6):360-373. PubMed ID: 36694914
[TBL] [Abstract][Full Text] [Related]
10. Single-cell sequencing reveals SATB2/NOTCH1 signaling promotes the progression of malignancy of epithelial cells from papillary thyroid cancer.
Zhang W; Wang J; Huang D; Liu Z; Lu T; Cui C; Li Z
Mol Carcinog; 2024 Jan; 63(1):22-33. PubMed ID: 37877736
[TBL] [Abstract][Full Text] [Related]
11. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways.
Xiao X; Chen M; Sang Y; Xue J; Jiang K; Chen Y; Zhang L; Yu S; Lv W; Li Y; Liu R; Xiao H
Thyroid; 2023 Dec; 33(12):1441-1454. PubMed ID: 37742107
[No Abstract] [Full Text] [Related]
12. SHMT2 promotes papillary thyroid cancer metastasis through epigenetic activation of AKT signaling.
Sun M; Zhao M; Li R; Zhang Y; Shi X; Ding C; Ma C; Lu J; Yue X
Cell Death Dis; 2024 Jan; 15(1):87. PubMed ID: 38272883
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of WWP1-mediated ubiquitination modification affecting proliferation and invasion/migration of liver cancer cells.
Zhang C; Wang W; Wu B
Kaohsiung J Med Sci; 2024 Mar; 40(3):255-268. PubMed ID: 37997542
[TBL] [Abstract][Full Text] [Related]
14. WWP1 E3 ligase at the crossroads of health and disease.
Behera A; Reddy ABM
Cell Death Dis; 2023 Dec; 14(12):853. PubMed ID: 38129384
[TBL] [Abstract][Full Text] [Related]
15. MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Liu Y; Xu S; Huang Y; Liu S; Xu Z; Wei M; Liu J
Int J Biol Sci; 2021; 17(13):3401-3412. PubMed ID: 34512155
[TBL] [Abstract][Full Text] [Related]
16. FLNA overexpression promotes papillary thyroid cancer aggression via the FAK/AKT signaling pathway.
Liang W; Zhang Y; Guo Y; Zhang P; Jin J; Guan H; Li Y
Endocr Connect; 2024 Jun; 13(6):. PubMed ID: 38614124
[TBL] [Abstract][Full Text] [Related]
17. GSG2 promotes thyroid cancer via stabilizing AURKB and activating AKT pathway.
Zhang F; Huang C
Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
[TBL] [Abstract][Full Text] [Related]
18. Regulatory and Interacting Partners of PDLIM7 in Thyroid Cancer.
Rood K; Yamauchi CR; Sharma U; Laxa RT; Robins C; Lanza G; Sánchez-Ruiz K; Khan A; Kim HS; Shields A; Kennedy K; Mirshahidi S; Perez MC; Firek A; Munir I; Simental AA; Khan S
Curr Oncol; 2023 Dec; 30(12):10450-10462. PubMed ID: 38132395
[TBL] [Abstract][Full Text] [Related]
19. New evidence on tumor suppressor activity of PTEN and KLLN in papillary thyroid carcinoma.
Razavi SA; Salehipour P; Gholami H; Sheikholeslami S; Zarif-Yeganeh M; Yaghmaei P; Modarressi MH; Hedayati M
Pathol Res Pract; 2021 Sep; 225():153586. PubMed ID: 34425332
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of PROS1 correlates with human papillary thyroid cancer progression.
Wang J; Lei M; Xu Z
PeerJ; 2021; 9():e11813. PubMed ID: 34414029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
